ArticlePloS one2025

Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab - the FAB-HCC pilot study.

Katharina Pomej et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.